This data suggests that the established Immunoscore may only capture the proportion of patients whose tumors are driven by CD8+ T-effector biology and that harnessing this alternative GZMB source from tumor cells is worth exploring as a biomarker and to uncover novel biology in CRC. The gene discussed is CD8A; the disease is neoplasm.